bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 5867: Examination of race/ethnicity differences in patient reported outcomes (PROs) among elderly female breast cancer patients in the SEER-MHOS database
Authors: Krebsbach Kendra R. , Stallion Chloe L. , Dookeran Keith A. 
Published: June 2022

Abstract
We use regression models to examine baseline differences in physical and mental health PROs [Physical and Mental Component Summary T-scores (PCS/MCS: are linear transformations of the 0-100 possible range scoring for 8 SF-36/VR-12 sub-scales, with mean of 50 and standard deviation (SD) of 10, normed to the US population)] among non-Hispanic black (NHB), non-Hispanic white (NHW), and Hispanic elderly female patients, with newly diagnosed breast cancer (BC) between 2010-2015 in the Surveillance, Epidemiology and End Results-Medicare Health Outcomes Survey (SEER-MHOS) database (a cancer registry that provides value health-related quality of life information on patients enrolled in Medicare Advantage). The study analytic sample consisted of 11,765 NHW, 1,988 NHB and 1,361 Hispanic women with overall mean age and BMI of 50.1 years (SD: 10.5) and 27.5 kg/m^2 (SD: 6.6), respectively. Compared with NHW both NHB and Hispanic women had significantly elevated BMI [NHB risk difference (RD) 3.43, 95% CI: 3.09, 3.77; Hispanic RD 0.84, 95% CI: 0.44, 1.24]; but significantly lower age at diagnosis [NHB RD -2.86, 95% CI: -3.36, -2.37; Hispanic RD -1.67, 95% CI: -2.26, -1.09]. Compared with NHW, both crude PCS and MCS scores were significantly worse for NHB and Hispanic women [PCS: NHB RD -4.26, 95% CI: -4.87, -3.65; Hispanic RD -3.29, 95% CI: -4.01, -2.56; MCS: NHB RD -3.79, 95% CI: -4.37, -3.22; Hispanic RD -4.09, 95% CI: -4.76, -3.43]. These differences also persisted after adjustment for BMI and age [compared with NHW, PCS: NHB RD -2.09, 95% CI: -2.76, -1.43; Hispanic RD -3.26, 95% CI: -4.06, -2.45; MCS: NHB RD -3.2, 95% CI: -3.86, -2.54; Hispanic RD -4.21, 95% CI: -4.99, -3.43]. There were however no significant differences in PCS or MCS scores between NHB and Hispanic women after adjustment for age and BMI. Our results show that elderly NHB and Hispanic women with BC in the SEER-MHOS database are significantly more likely to have poorer physical and mental outcomes compared with NHW. However, this PRO disparity was not evident between NHB and Hispanic women and requires further exploration.
Citation Format: Kendra R. Krebsbach, Chloe L. Stallion, Keith A. Dookeran. Examination of race/ethnicity differences in patient reported outcomes (PROs) among elderly female breast cancer patients in the SEER-MHOS database [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5867.
Abstract 5868: Factors associated with exercise participation in patients with breast cancer
Authors: Marell Paulina S. , Olson Janet E. , Herrmann Joerg , Larson Nicole L. , LeBrasseur Nathan K. , D'Andre Stacy D. , Cheville Andrea L. , Barksdale Toure , Loprinzi Charles L. , Couch Fergus J. , Ruddy Kathryn J. 
Published: June 2022

Abstract
BACKGROUND: The American Cancer Society recommends at least 150 minutes of moderate and/or strenuous exercise and muscle-strengthening activities each week for adults. Exercise has been associated with decreased breast cancer mortality and adverse symptoms. This study’s purpose is to understand prevalence and predictors of inadequate aerobic exercise in patients recently diagnosed with breast cancer to inform interventions to increase exercise participation.
METHODS: Patients seen at least once at Mayo Clinic Rochester were prospectively enrolled within one year of an initial breast cancer diagnosis in the Mayo Clinic Breast Disease Registry after providing informed consent. This analysis includes those who completed a baseline survey with self-reported exercise data using the Godin Leisure-Time Exercise Questionnaire. This longitudinal cohort study was approved by the Mayo Clinic institutional review board.
RESULTS: 1,738 participants reported their usual weekly quantity of moderate and strenuous exercise an average of 95 days (SD 71 days, range 0-365) after diagnosis. Table 1 displays participant characteristics overall and by whether participants reported at least 150 minutes of moderate and/or strenuous activity weekly (“met guidelines”) or not (“did not meet guidelines”). Overall, 39% of participants met guidelines, including 56% of those aged 18-39 years, 40% of those aged 40-69 years, and 27% of those aged 70+ years.
CONCLUSION: Older age was associated with less likelihood of meeting exercise guidelines (all age groups vs 70+, p &lt; 0.05). A more diverse cohort will be needed to evaluate differences by gender and race/ethnicity. There did not appear to be any obvious impact on exercise level by time since diagnosis (during the first year after diagnosis) or educational status, though substantial missing data limit conclusions related to the latter. Additional research is needed to assess exercise levels later in survivorship and the impact of various treatment modalities on exercise habits
Table 1. Patient and tumor characteristics
Citation Format: Paulina S. Marell, Janet E. Olson, Joerg Herrmann, Nicole L. Larson, Nathan K. LeBrasseur, Stacy D. D'Andre, Andrea L. Cheville, Toure Barksdale, Charles L. Loprinzi, Fergus J. Couch, Kathryn J. Ruddy. Factors associated with exercise participation in patients with breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5868.
Abstract 5880: Diabetes incidence after obesity-related cancer diagnosis and survival in the women’s health initiative
Authors: Karra Prasoona , Winn Maci , Haaland Benjamin , Anderson Garnet , Thomson Cynthia A. , Shadyab Aladdin H. , Luo Juhua , Saquib Nazmus , Strickler Howard , Chlebowski Rowan , Arthur Rhonda , Hardikar Sheetal , Playdon Mary C. 
Published: June 2022

Abstract
Introduction: Obesity-related cancer (ORC) diagnosed individuals are at an elevated risk of new-onset diabetes compared with cancer-free individuals. However, less is known about mortality among those with incident type 2 diabetes after cancer.
Methods: In the Women’s Health Initiative (N=14,455 ORC cases), we measured the association of incident type 2 diabetes diagnosed 0-1 years, &gt;1-3, &gt;3-5, &gt;5-7 and &gt;7-10 years after ORC diagnosis with cancer-specific and overall mortality using stratified Cox proportional hazards regression analysis.
Results: The participants were post-menopausal females with ORC and predominantly white. The number of WHI participants with ORC who developed diabetes after cancer diagnosis were: 0-1 years - 205/12992 (1.58%); 1-3 years - 326/11322 (2.88%); 3-5 years - 276/9784 (2.82%); 5-7 years - 268/8420 (3.18%); and 7-10 years - 510/6419 (7.95%). The median survival after the first year of cancer diagnosis for participants without diabetes was 16.6 years (95% CI: 16.17-17.0 years) and for those with diabetes was 10.3 years (95% CI: 7.97-14.9 years). New-onset diabetes after ORC diagnosis showed elevated overall mortality and cancer-specific mortality when compared with no diabetes diagnosis.
Conclusions: Incident type 2 diabetes is associated with worse cancer-specific and overall survival, particularly in the year after diagnosis, among women with ORC.
Type 2 Diabetes from time since cancer diagnosis Overall mortality HR (95% CI)a Cancer-specific mortality HR (95% CI)a 0-1 years 1.79 (1.41-2.29) 1.56 (1.04-2.34) &gt;1-3 years 1.22 (0.99-1.51) 1.05 (0.72-1.55) &gt;3-5 years 1.21 (0.95-1.55) 1.37 (0.89-2.12) &gt;5-7 years 1.02 (0.78-1.33) 0.80 (0.47-1.36) &gt;7-10 years 1.10 (0.87-1.40) 0.97 (0.59-1.60) aModel adjusted for demographics (age, education, race/ethnicity, marital status), body mass index (BMI)) and cancer characteristics (cancer type, stage, grade). CI = confidence interval; HR = Hazard ratio.
Citation Format: Prasoona Karra, Maci Winn, Benjamin Haaland, Garnet Anderson, Cynthia A. Thomson, Aladdin H. Shadyab, Juhua Luo, Nazmus Saquib, Howard Strickler, Rowan Chlebowski, Rhonda Arthur, Sheetal Hardikar, Mary C. Playdon. Diabetes incidence after obesity-related cancer diagnosis and survival in the women’s health initiative [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5880.
Abstract 5921: Machine learning based detection of pancreatic tumors using the Dxcover® cancer platform
Authors: Sala Alexandra , Cameron James M. , Jenkins Cerys A. , Barr Hugh , Christie Loren , Conn Justin J. , Evans Thomas (Jeff) R. , Harris Dean A. , Palmer David S. , Rinaldi Christopher , Theakstone Ashton G. , Baker Matthew J. 
Published: June 2022

Abstract
Pancreatic cancer is the 7th most deadly cancer worldwide with over 460,000 victims per year. In the current diagnostic pathway, carbohydrate antigen (CA) 19-9 serum test is the first method used for detection of pancreatic cancer; although, with poor positive predictive values reported, it cannot provide certain information about the presence of a pancreatic tumor or other surrounding tumors in symptomatic patients. Attenuated total reflection - Fourier transform infrared spectroscopy (ATR-FTIR) has demonstrated exceptional potential in human blood serum analysis for cancer diagnostics and its implementation in the clinical environment could represent a significant step forward in the early detection of pancreatic cancer. This proof-of-concept study was focused on the discrimination between both cancer versus healthy control samples, and cancer versus symptomatic control samples from patients with comorbidities and/or confounding diseases. The study aimed to investigate the use of the Dxcover® cancer platform as a novel approach for pancreatic cancer detection. Various machine learning algorithms were applied to discriminate between cancer (n=100) and healthy control samples (n=100), achieving results amounting to a sensitivity of 91.0 ± 5.6%, specificity of 87.6 ± 5.8%, and accuracy of 89.3 ± 3.8% with partial least squares-discriminant analysis (PLS-DA). Moreover, an area under the curve (AUC) equal to 0.9536 was obtained through receiving operating characteristic (ROC) analysis. The same algorithms were also applied to discriminate between cancer (n=35) and symptomatic control samples (n=35) achieving a balanced sensitivity and specificity over 75% with an AUC of 0.8436. Both discriminations underwent bootstrapping validation and were proven statistically significant. Herein, we present these results and demonstrate that ATR-FTIR spectroscopic analysis of serum is a cost-effective, minimally invasive, highly sensitive and specific test for detection of pancreatic cancer.
Citation Format: Alexandra Sala, James M. Cameron, Cerys A. Jenkins, Hugh Barr, Loren Christie, Justin J. Conn, Thomas (Jeff) R. Evans, Dean A. Harris, David S. Palmer, Christopher Rinaldi, Ashton G. Theakstone, Matthew J. Baker. Machine learning based detection of pancreatic tumors using the Dxcover® cancer platform [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5921.
Abstract 5926: Hepatocellular carcinoma in the hepatitis B vaccinated and nonvaccinated age groups in The Gambia
Authors: Bittaye Sheikh Omar , Njie Ramou 
Published: June 2022

Abstract
INTRODUCTION: Hepatitis B vaccination was started in The Gambia in July 1986 and nationwide coverage was achieved in February1990. However not much is known about its effect in the prevention of Hepatocellular carcinoma (HCC) in The Gambia.
OBJECTIVE: We assess the differences in the features of HCC in both the Hepatitis B vaccinated and non-vaccinated age groups in The Gambia.
METHOD: Patients with suspected HCC who were referred to the main liver clinic at the Medical Research Council, Gambia Unit (MRCG) were recruited from June 2011 to September 2019. The diagnostic criteria for HCC comprised of ultrasound demonstration of liver mass ≥2 cm with or without clinical features combined with alpha-fetoprotein (AFP) level of ≥200 ng/ml and/or histopathological confirmation. Clinical, radiological, fibroelastrography and laboratory data were collected in all patients.
RESULTS: Five hundred and forty two patients were recruited into the study. The majority (91.3%) of the patients were in the non-vaccinated age group and most (88.8%) were born in The Gambia. Those born outside The Gambia were mostly Senegalese, Sierreleonean, and Guineans. The patients in the vaccinated age group were much younger and less likely to be born in The Gambia. They were also more likely to have higher AFP levels, positive HBsAg and a lower creatinine level as compared to those patients in the non-vaccinated age group. There was no difference in clinical manifestations, Liver Function tests and median survival.
CONCLUSIONS: The early introduction of Nationwide Hepatitis B vaccination in 1990 into the EPI program in The Gambia may have had a positive effect in the incidence of Hepatocellular Carcinoma in the vaccinated age group. Compared to neighbouring countries, The Gambia seems to be leading the path for Hepatitis B elimination.To strengthen these gains, a nationwide screening and treatment program needs to be implemented for those in the non-vaccinated age groups.
Citation Format: Sheikh Omar Bittaye, Ramou Njie. Hepatocellular carcinoma in the hepatitis B vaccinated and nonvaccinated age groups in The Gambia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5926.
Abstract 5930: Identifying effective communication for recruitment of minority women to a breast cancer prevention study: A novel focus group approach
Authors: Ridley-Merriweather Katherine E. , Younker Stephanie M. , Evans Madeline D. , Wu Cynthia Y. 
Published: June 2022

Abstract
Ensuring that minoritized women are involved in breast cancer research is important to address well-documented current disparities in cancer incidence, stages of diagnosis, and mortality rates. This study used a novel interactive focus group method to identify innovative communication strategies for recruiting women from two minority groups—Latinas and Asian Americans—into the Komen Tissue Bank, a specific breast cancer biobank clinical trial. Through activities that employed visual interactive tools to facilitate group discussion and self-reflection, the authors examined perspectives and motivations for Asian American women (N=17) and Latinas (N=14) toward donating their healthy breast tissue. Findings included three themes that, while common to both groups, were unique in how they were expressed: lack of knowledge concerning breast cancer risks and participation in clinical research, cultural influences in breast cancer risk thinking, and how altruism relates to perceived personal connection to breast cancer. More significantly, this study illuminated the importance of using innovative methods to encourage deeper, more enlightened participation among underrepresented populations that may not arise in a traditional focus group format. The findings from this study will inform future health communication efforts to recruit women from these groups into clinical research projects like the Komen Tissue Bank. These findings also illustrate the importance of applying rigorous qualitative work to supplement quantitative research to increase the inclusion of minoritized populations in clinical trials.
Citation Format: Katherine E. Ridley-Merriweather, Stephanie M. Younker, Madeline D. Evans, Cynthia Y. Wu. Identifying effective communication for recruitment of minority women to a breast cancer prevention study: A novel focus group approach [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5930.
Abstract 5931: Development and validation of a novel circulating cell-free microRNA diagnostic model with high accuracy for multi-cancer early detection
Authors: Zhang Andrew , Hu Hai 
Published: June 2022

Abstract
Introduction: Early detection is critical to reduce cancer deaths as treating early stage cancers is more likely to be successful. We aimed to develop and validate a noninvasive blood-based diagnostic model capable of detecting multiple cancers by assessing the expression levels of serum microRNAs (miRNAs).
Patients and Methods: Four microarray datasets assessing expression profiles of 2588 serum miRNAs with a standardized platform were assembled from Gene Expression Omnibus (GEO) totaling 7536 participants including 3604 cancer patients across 13 cancer types and 3932 non-cancer controls. A diagnostic model was built in a training set of 416 participants, including 208 lung cancer patients and 208 non-cancer controls matched for age, sex, and smoking history. The model performance was assessed in the validation sets consisting of all the remaining 7120 participants.
Results: A 4-miRNA diagnostic model was developed from the lung cancer training set. The model showed 99% sensitivity and specificity in the lung cancer validation set (n=3328, 1358 cancer & 1970 non-cancer participants); and the sensitivity remained to be &gt;99% for patients with stage 1 disease. When applied to the additional dataset of 3792 participants including 2038 cancer patients across 12 cancer types and 1754 independent non-cancer controls, the model showed high sensitivities ranging from 83⋅2% to 100% for biliary tract, bladder, colorectal, esophageal, gastric, glioma, liver, pancreatic, and prostate cancers, and reasonable sensitivities of 68⋅2% and 72⋅0% for ovarian cancer and sarcoma, respectively, while maintaining 99⋅3% specificity (Table 1).
Conclusion: The study provided a proof-of-concept demonstrating that the 4-miRNA model has the potential to be developed into a simple, inexpensive and noninvasive blood test for early detection of multiple cancers with high accuracy.
Table 1. Sensitivities of the 4-miRNA diagnostic model in 12 cancer types. N Sensitivity Lung Cancer 1358 99.3% Biliary Tract Cancer 40 97.5% Bladder Cancer 392 98.2% Colorectal Cancer 155 85.8% Esophageal Cancer 124 84.7% Gastric Cancer 150 100% Glioma 40 87.5% Liver Cancer 348 84.2% Ovarian Cancer 333 68.2% Pancreatic Cancer 149 83.2% Prostate Cancer 40 92.5% Sarcoma 132 72.0%
Citation Format: Andrew Zhang, Hai Hu. Development and validation of a novel circulating cell-free microRNA diagnostic model with high accuracy for multi-cancer early detection [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5931.
Abstract 5935: Malignant risk assessment of clinical and histological subtypes of lichenoid mucositis with dysplasia
Authors: Lin Iris , Kim Oh Run , Rock Leigha , Zhang Lewei , Rosin Miriam , Guillaud Martial , Laronde Denise 
Published: June 2022

Abstract
Introduction: Oral lichen planus (OLP), a common, chronic inflammatory condition, is categorized as potentially malignant by the World Health Organization. However, some hypothesize that only lichenoid lesions with dysplasia (LLD) are at risk of progression to cancer. Others have proposed subtypes of LLD, with differing malignant risks. Objectives: To determine if subtypes of LLD exist, based on clinical and histological features, and to determine the proportion of malignant progression in these subtypes. Methods: A nested case control study was conducted using tissue samples and longitudinal data of patients enrolled in the Oral Cancer Prediction Longitudinal study. Inclusion criteria were a biopsy confirmed diagnosis of lichenoid mucositis with dysplasia, no history of head and neck cancer, at least 5 years of follow-up, and accessible clinical photographs and bio-banked tissue. A chart review was conducted, and photographs reviewed to assess for lesion features characteristic of OLP. Histological sections were examined for lichenoid inflammation, and immunohistochemical staining for collagen IV was used to evaluate the integrity of the basement membrane (BM). Two subtypes of LLD were proposed: 1) a primary lichenoid and secondary dysplastic (L1D2) type defined as a lesion with a reticular and bilateral clinical presentation, subepithelial inflammation, and evidence of BM degeneration, and 2) a primary dysplastic and secondary lichenoid type (D1L2), which may present unilaterally or bilaterally, clinically resemble OLP or leukoplakia, and exhibit subepithelial inflammation with or without evidence of BM degeneration. Association with outcome, which was defined as progression to severe dysplasia, carcinoma in situ, or squamous cell carcinoma, was tested using Fisher’s Exact test. Results: All progressing cases had a non-homogenous clinical presentation (P=0.005) and were more apt to change (in size, texture, and/or appearance) over time (P=0.002). A reticular, smooth appearance was more common in non-progressing cases (P=0.007, P=0.016, respectively). 30% of cases in the D1L2 subtype progressed to malignancy, compared to none in the L1D2 group, though this finding did not reach statistical significance (P=0.081). Conclusion: LLD with a non-homogenous, non-reticular clinical presentation are at greater risk of progression, and a high proportion of cases exhibiting primary dysplastic features progressed to malignancy, indicating that LLD should be under close clinical follow-up.
Citation Format: Iris Lin, Oh Run Kim, Leigha Rock, Lewei Zhang, Miriam Rosin, Martial Guillaud, Denise Laronde. Malignant risk assessment of clinical and histological subtypes of lichenoid mucositis with dysplasia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5935.